FibroGen, Inc is a biotechnology business based in the US. FibroGen shares (FGEN) are listed on the NASDAQ and all prices are listed in US Dollars. FibroGen employs 599 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in FibroGen
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – FGEN – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
FibroGen stock price (NASDAQ: FGEN)Use our graph to track the performance of FGEN stocks over time.
FibroGen shares at a glance
|Latest market close||$21.25|
|52-week range||$12.54 - $57.21|
|50-day moving average||$23.37|
|200-day moving average||$30.83|
|Wall St. target price||$36.71|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.46|
Buy FibroGen shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy FibroGen stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
FibroGen price performance over time
|1 week (2021-07-20)||N/A|
|1 month (2021-07-01)||-19.81%|
|3 months (2021-04-30)||-4.79%|
|6 months (2021-01-27)||N/A|
|1 year (2020-07-27)||N/A|
|2 years (2019-07-27)||N/A|
|3 years (2018-07-27)||N/A|
|5 years (2016-07-27)||N/A|
Is FibroGen under- or over-valued?
Valuing FibroGen stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of FibroGen's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
FibroGen's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $49.3 million.
The EBITDA is a measure of a FibroGen's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$190.3 million|
|Gross profit TTM||$-85,474,000|
|Return on assets TTM||-14.06%|
|Return on equity TTM||-42.1%|
|Market capitalisation||$1.2 billion|
TTM: trailing 12 months
Shorting FibroGen shares
There are currently 7.3 million FibroGen shares held short by investors – that's known as FibroGen's "short interest". This figure is 4.4% down from 7.7 million last month.
There are a few different ways that this level of interest in shorting FibroGen shares can be evaluated.
FibroGen's "short interest ratio" (SIR)
FibroGen's "short interest ratio" (SIR) is the quantity of FibroGen shares currently shorted divided by the average quantity of FibroGen shares traded daily (recently around 1.0 million). FibroGen's SIR currently stands at 7.1. In other words for every 100,000 FibroGen shares traded daily on the market, roughly 7100 shares are currently held short.
However FibroGen's short interest can also be evaluated against the total number of FibroGen shares, or, against the total number of tradable FibroGen shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case FibroGen's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 FibroGen shares in existence, roughly 80 shares are currently held short) or 0.0856% of the tradable shares (for every 100,000 tradable FibroGen shares, roughly 86 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against FibroGen.
Find out more about how you can short FibroGen stock.
FibroGen share dividends
We're not expecting FibroGen to pay a dividend over the next 12 months.
FibroGen share price volatility
Over the last 12 months, FibroGen's shares have ranged in value from as little as $12.54 up to $57.2088. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while FibroGen's is 1.0277. This would suggest that FibroGen's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
FibroGen, Inc. , a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase II trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc.
Stocks similar to FibroGen
FibroGen in the news
FibroGen (FGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
FibroGen to Report Second Quarter 2021 Financial Results
What's Next for FibroGen After an FDA Vote Against Its Anemia Drug?
Frequently asked questionsWhat percentage of FibroGen is owned by insiders or institutions?
Currently 7.919% of FibroGen shares are held by insiders and 79.095% by institutions. How many people work for FibroGen?
Latest data suggests 599 work at FibroGen. When does the fiscal year end for FibroGen?
FibroGen's fiscal year ends in December. Where is FibroGen based?
FibroGen's address is: 409 Illinois Street, San Francisco, CA, United States, 94158 What is FibroGen's ISIN number?
FibroGen's international securities identification number is: US31572Q8087 What is FibroGen's CUSIP number?
FibroGen's Committee on Uniform Securities Identification Procedures number is: 31572Q808
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert